← Russell 3000 cross-section

AMPH Amphastar Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$927m
Revenue TTM
$730m
Net income TTM
$78m
Free cash flow
$153m
Composite score
83.5
Sector rank
#2054

Valuation

P / E
11.8
EV / EBITDA
3.7
EV / sales
0.9
FCF yield
16.49%
Earnings yield vs 10-yr
3.74pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
10.8%
EBITDA margin
23.5%
ROE
10.2%
ROIC
23.9%
Revenue growth
1.0%

Insider activity, last 90 days

Net open-market
$-0.35m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Segment Reporting.” ​ Results of Operations ​ Three Months Ended June 30, 2026 compared to Three Months Ended June 30, 2025 ​ Net revenues ​ ​ The following table summarizes our revenue by product for the three months ended June 30, 2026 and 2025: ​ -32- ​ In April 2026, we launched our ipratropium bromide HFA inhalation aerosol, which was approved by the FDA in February 2026. ​ The decrease in sales of BAQSIMI ® during the quarter was primarily due to a lower average selling price, as a result of a change in gross-to-net discounts due to changes in chargebacks and rebates and changes to the customer mix, impacting sales of approximately $8.1 million. …Amphastar Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →